Skip to main content

Allakos Inc. Common Stock (ALLK)

About The Company

ALLK Stock Market Logo

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company’s lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibitmast cells.

IPO Year Sector Industry
2018 Health Care Biotechnology: Pharmaceutical Preparations

Allakos Inc. (ALLK) Latest News

Company Contact & Address (ALLK)

Corporate Headquarters Phone Website
United States
+1 650 597-5002 Official ALLK Website

ALLK Key Executives

Ownership and management information.

Key Data Points*

Exchange Not Available Market Cap Not Available
Sector Health Care P/E Ratio Not Available
Industry Biotechnology: Pharmaceutical Preparations Forward P/E 1 Yr. Not Available
1 Year Target Not Available Earnings Per Share (EPS) Not Available
Today’s High/Low Not Available Annualized Dividend Not Available
Share Volume Not Available Ex Dividend Date Not Available
Average Volume Not Available Dividend Pay Date Not Available
Previous Close Not Available Current Yield Not Available
52 Week High/Low Not Available Beta Not Available

* Information and data may delayed

Officers & Directors @ ALLK

Jobs & Employment at Allakos Inc.

LinkedIn Company Page
Official Career & Employment Page Employment & Jobs at Allakos Inc. (ALLK)

Related & Similar Stock Symbols

IMPL Stock Market Price & News


Impel Pharmaceuticals Inc. Common Stock

BSGM Stock Market Price & News


BioSig Technologies Inc. Common Stock

WFCF Stock Market Price & News


Where Food Comes From Inc. Common Stock